Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer

Fineline Cube Jul 23, 2026
Company Drug

Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer

Fineline Cube Jul 23, 2026
Policy / Regulatory

China’s Health Authorities Set Standards for Key Central Township Health Centers

Fineline Cube Aug 1, 2024

The National Health Commission (NHC), National Disease Control and Prevention Administration, and National Administration of...

Policy / Regulatory

China’s State Council Unveils Five-Year Plan to Enhance Urbanization and Address “Three Rural Issues”

Fineline Cube Aug 1, 2024

The State Council of China has released a “Five Year Action Plan for Deepening the...

Policy / Regulatory

Shanghai Aims to Become Capital Market Hub for High-Quality Science and Innovation Companies

Fineline Cube Aug 1, 2024

The Shanghai municipal government has unveiled a comprehensive set of measures designed to enhance the...

Company Deals Legal / IP

Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations

Fineline Cube Aug 1, 2024

Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation...

Company Medical Device

MicroPort Scientific’s Bioabsorbable Stent System Gains NMPA Nod for Ischemic Heart Disease Treatment

Fineline Cube Aug 1, 2024

Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company

HutchMed Reports 2024 H1 Financials with Mixed Results Amid Strategic Focus on R&D and Commercial Efficiency

Fineline Cube Aug 1, 2024

China-based HutchMed (NASDAQ: HCM) has released its financial report for the first half of 2024,...

Company Drug

Tonghua Dongbao Pharmaceuticals Launches Phase III Clinical Trial for Semaglutide Biosimilar in China

Fineline Cube Aug 1, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the commencement of a...

Company Deals

Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program

Fineline Cube Aug 1, 2024

China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA...

Company Deals

Pfizer Enters Multi-Year R&D Collaboration with Telescope Innovations to Leverage AI and Robotics

Fineline Cube Aug 1, 2024

Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has entered into a multi-year collaborative...

Company

GSK Reports Q2 2024 Earnings with 13% Growth, Vaccines Unit Sees Mixed Results

Fineline Cube Aug 1, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has reported its financial results for...

Company

Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches

Fineline Cube Aug 1, 2024

Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...

Company Drug Policy / Regulatory

NICE and AstraZeneca Fail to Reach Agreement on Enhertu Reimbursement for NHS

Fineline Cube Aug 1, 2024

The UK’s National Institute for Health and Care Excellence (NICE) has announced that negotiations with...

Policy / Regulatory

Shanghai Unveils Comprehensive Measures to Strengthen Biopharmaceutical Industry

Fineline Cube Aug 1, 2024

The Shanghai municipal government has issued a comprehensive set of measures aimed at bolstering the...

Company

Takeda Reports 3.7% YOY Revenue Growth in Q1 2023 Fiscal Year with Priority Products Driving Sales

Fineline Cube Aug 1, 2024

Japan-based multinational Takeda (TYO: 4502) has released its financial report for the fiscal year 2023...

Company Drug

BioNTech’s mRNA Cancer Immunotherapy BNT111 Achieves Primary Endpoint in Phase II Trial

Fineline Cube Jul 31, 2024

Germany-based BioNTech SE (NASDAQ: BNTX) has announced that its mRNA cancer immunotherapy BNT111, in combination...

Company

Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak

Fineline Cube Jul 31, 2024

Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for...

Company

Merck’s Q2 2024 Earnings Miss Estimates as China Market Downturn Surprises

Fineline Cube Jul 31, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has reported its financial results for the...

Company Drug

FibroGen Inc. Enters Restructuring Mode After Late-Stage Trial Failures for Pamrevlumab

Fineline Cube Jul 31, 2024

US-based biotechnology company FibroGen Inc. (NASDAQ: FGEN), which maintains significant operations in China, is initiating...

Company Deals

National Comprehensive Cancer Network Renews Partnership with Medlive for Oncology Guidelines Access in China

Fineline Cube Jul 31, 2024

The National Comprehensive Cancer Network (NCCN), a leading non-profit academic organization in the US, has...

Policy / Regulatory

China’s NHSA and NHC to Integrate Village Clinics into Basic Medical Insurance System

Fineline Cube Jul 31, 2024

The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) of China have...

Posts pagination

1 … 353 354 355 … 698

Recent updates

  • Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring
  • GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer
  • Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer
  • Ribo Life Science Reports Positive Phase 2a Results for Vortosiran in Chronic Coronary Artery Disease
  • Johnson & Johnson Secures FDA De Novo Authorization for OTTAVA™ – World’s First Table-Integrated Robotic Surgical System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Company Drug

GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer

Company Drug

Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer

Company Drug

Ribo Life Science Reports Positive Phase 2a Results for Vortosiran in Chronic Coronary Artery Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.